CAR-T cell therapy for severe ulcerative colitis
Part of Immune system & allergy clinical trials.
This trial tests a new treatment using your own immune cells (called CAR-T cells) to calm down the immune attack that causes ulcerative colitis. It is for people with moderate to severe colitis who have not gotten better with standard medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with moderate to severe ulcerative colitis.
- You have tried all approved UC treatments in China and they did not work.
- You have a Mayo score of 6-12 and an endoscopic score of at least 2.
- Your blood, liver, kidney, heart, lung, and clotting tests are within safe limits.
- You are not pregnant or breastfeeding.
- You do not have active infections like hepatitis B, C, HIV, or tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to treat inflammatory bowel disease (IBD) that has not responded to standard treatments. The therapy is engineered to target specific immune cells involved in IBD inflammation.
This trial tests a new type of immune cell therapy called CAR-T cells, which target two proteins (CD19 and BCMA) to reduce inflammation in the gut. It is designed for adults with moderate to severe ulcerative colitis or Crohn's disease that has not responded well to other treatments.
This trial tests a new kind of cell therapy (UCAR-T) that targets CD19 and BCMA proteins on immune cells. It is for people with certain neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis who have not responded well to standard treatments.
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
This trial tests a new treatment called CAR-T cells that target two proteins (BCMA and CD19) on immune cells. It is for people with certain autoimmune diseases that have not improved with standard treatments.
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
Hear when a new UC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.